Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Brentuximab Vedotin Plus Chemotherapy Works as a Primary Option for Hodgkin Lymp...
Pierluigi Porcu, MD, explained how the combination of brentuximab vedotin plus chemotherapy works in in frontline setting of Hodgkin lymphoma during a virtual Targeted Oncology Case-Based Roundtable event.
Relapsed/Refractory DLBCL Undergoes Rapid Evolution With CAR T-Cell Therapy, ADC...
High-dose chemotherapy and transplant remains the second-line standard of care for the majority of patients with relapsed/refractory diffuse large B-cell lymphoma; however, CAR T-cell therapy and other novel agents, which have transformed the third-line setting, may offer alternative and more personalized second-line options in the coming years.
Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are this week's must-read highlights.
Monoclonal Antibodies Prove to Be Novel Therapeutics for Myeloma
Novel drugs have especially improved the treatment options for relapsed myeloma, with some agents now also being used as frontline therapy. As a result, outcomes for patients with newly diagnosed and relapsed disease continue to improve with prolongation of median survival to greater than 7 years from diagnosis.
HDP-101, an antibody-targeted amanitin conjugate to advance to phase I/IIa testi...
The U.S. Food and Drug Administration (FDA) has announced that the B-cell maturation antigen (BCMA) antibody–drug conjugate HDP-101 can proceed to phase I/IIa testing.
First-in-human trial of an anti-BCMA ADC for R/R myeloma
Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, discusses the results of a Phase I, first-in-human dose-escalation trial (NCT03489525) of MEDI2228 in patients with relapsed/refractory (R/R) multiple myeloma.